Vijenthira, A; Gong, IY; Fox, TA; Booth, S; Cook, G; Fattizzo, B; Martin Moro, F; ... Hicks, LK; + view all Vijenthira, A; Gong, IY; Fox, TA; Booth, S; Cook, G; Fattizzo, B; Martin Moro, F; Razanamahery, J; Riches, JC; Zwicker, JI; Patell, R; Vekemans, M-CM; Scarfo, L; Chatzikonstantinou, T; Yildiz, H; Lattenist, R; Mantzaris, I; Wood, WA; Hicks, LK; - view fewer (2020) Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients. Blood , 136 (25) pp. 2881-2892. 10.1182/blood.2020008824.

Preview

Text Fox_Outcomes of patients with hematologic malignancies and COVID.pdf - Accepted Version Download (1MB) | Preview

Abstract

Outcomes for patients with hematologic malignancy infected with COVID-19 have not been aggregated. The objective of this study was to perform a systematic review and meta-analysis to estimate the risk of death and other important outcomes for these patients. We searched Pubmed and EMBASE up to August 20, 2020, to identify reports of patients with hematologic malignancy and COVID-19. The primary outcome was a pooled mortality estimate, considering all patients and only hospitalized patients. Secondary outcomes included risk of ICU admission and ventilation in hospitalized patients. Subgroup analyses included mortality stratified by age, treatment status, and malignancy subtype. Pooled prevalence, risk ratios (RR), and 95% confidence intervals (CI) were calculated using a random-effects model. 34 adult and 5 pediatric studies (3377 patients) from Asia, Europe, and North America were included (14/34 adult studies included only hospitalized patients). The risk of death amongst adult patients was 34% (95% CI 28-39, N=3240) in this sample of predominantly hospitalized patients. Patients aged >60 years had a significantly higher risk of death than patients <60 years (RR 1.82, 95% CI 1.45-2.27, N=1169). The risk of death in pediatric patients was 4% (95% CI 1-9, N=102). The RR of death comparing patients with recent systemic anti-cancer therapy to no treatment was 1.17 (95% CI 0.83-1.64; N=736). Adult patients with hematologic malignancy and COVID-19, especially hospitalized patients, have a high risk of dying. Patients >60 years have significantly higher mortality, and pediatric patients appear to be relatively spared. Recent cancer treatment does not appear to significantly increase the risk of death.

Download activity - last month

Export as CSVXMLJSON

Download activity - last 12 months

Export as XMLCSVJSON

Downloads by country - last 12 months

Export as XMLCSVJSON

Archive Staff Only

View Item